Eledon pharmaceuticals announces 12th participant enrolled in phase 2 bestow trial evaluating tegoprubart for the prevention of organ rejection

Irvine, calif., march 25, 2024 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today announced the enrollment of the 12th participant on march 23, 2024, in the company's ongoing phase 2 bestow trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.
ELDN Ratings Summary
ELDN Quant Ranking